Bronchiectasis trials: losing the battle but winning the war?

The Lancet Respiratory Medicine

Volumn 2, Issue 9, 2014, Pages 679-681

  Chalmers, James D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; COLISTIN; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AIRWAY NEUTROPHILIC INFLAMMATION; ANTIINFLAMMATORY ACTIVITY; BACTERIAL LOAD; BRONCHIECTASIS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE BACTERIUM; HUMAN; NOTE; OUTCOME ASSESSMENT; PHENOTYPE; QUALITY OF LIFE; QUALITY OF LIFE BRONCHIECTASIS QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; TREATMENT FAILURE; FEMALE; MALE;

ANTI-BACTERIAL AGENTS; AZTREONAM; BRONCHIECTASIS; FEMALE; HUMANS; MALE;

EID: 84908069156     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70181-X     Document Type: Note

References (10)

1. Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013, 144:215-225. B301 Investigators.
2. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014, 189:975-982.
3. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution (AZLI) in patients with non-CF bronchiectasis: the results from two randomized double blind placebo controlled phase 3 trials. Lancet Respir Med 2014, published online Aug 19. http://dx.doi.org/10.1016/S2213-2600(14)70165-1.
4. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
5. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
6. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
7. Chalmers JD, Smith MP, McHugh B, Doherty C, Govan JRW, Hill AT Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012, 186:657-665.
8. Murray MP, Govan JRW, Docherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
9. Chalmers JD, Goeminne P, Aliberti S, et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2014, 189:576-585.
10. O'Donnell AE, Barker AF, Ilowite JS, Fick RB Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113:1329-1334.